Cornerstone Buys EKR Therapeutics To Expand Hospital Growth Strategy
This article was originally published in The Pink Sheet Daily
Executive Summary
Cornerstone gains two commercial products for the acute-care hospital setting, Cardene and Retavase, with the acquisition of EKR Therapeutics for $125 million upfront and potential milestones.